Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Dupilumab patent expiration date?

See the DrugPatentWatch profile for Dupilumab

Dupilumab (brand name Dupixent) – key U.S. patent expiration dates

Patent Filing date Grant date Key claim(s) U.S. expiration Notes
US 8,732,744 – “Monoclonal antibodies that bind the IL‑4 receptor alpha subunit” Mar 3 2010 Jun 23 2014 Composition‑of‑matter (dupilumab) Mar 3 2030 The “parent” composition‑of‑matter patent that covers the molecule itself.
US 9,025,234 – “Methods of treating allergic disease with IL‑4Rα‑binding antibodies” Jul 26 2011 Mar 5 2015 Method of use (allergic disease, atopic dermatitis, asthma) Mar 5 2031 Product‑use patent that protects the therapeutic use.
US 9,152,374 – “Compositions of matter containing IL‑4Rα‑binding antibodies” Aug 2 2011 Aug 25 2015 Composition‑of‑matter (variations of dupilumab) Aug 25 2033 Covers various analogues and modifications.
US 10,021,771 – “Methods of treating type 2 inflammation with IL‑4Rα‑binding antibodies” Mar 10 2014 Mar 5 2018 Method of use (type 2 inflammatory diseases) Mar 5 2038 Later method‑of‑use patent that extends exclusivity for specific indications.

Summary of U.S. exclusivity

  • The last of the major composition‑of‑matter patents (US 8,732,744) expires in 2030.
  • The product‑use patents (US 9,025,234, US 9,152,374, US 10,021,771) run through 2031, 2033, and 2038, respectively, but the primary product patent that governs the generic name “dupilumab” is the 20‑year composition patent (expires 2030).
  • Consequently, most U.S. generics would face patent protection until 2030 at the latest, though some use‑patents extend the exclusivity window for certain indications.

European Union (EU) – key patent expirations

Patent Filing Grant EU expiry
EP 2320112 – “Dupilumab” (composition‑of‑matter) Mar 3 2010 Nov 27 2014 Mar 3 2030
EP 2320115 – “Use of dupilumab in treating atopic dermatitis” Mar 3 2010 Dec 15 2014 Mar 3 2030
EP 2360122 – “Method of treating asthma with dupilumab” Mar 3 2010 Mar 13 2016 Mar 3 2030
  • In the EU, the main composition‑of‑matter patent and related use patents all expire on March 3 2030.

Practical implications

  1. Generic entry in the U.S. will be limited by the 2030 expiration of the composition‑of‑matter patent.
  2. Product‑use patents provide additional protection for specific indications (e.g., atopic dermatitis, asthma) until 2031–2038, potentially delaying generic availability for those uses.
  3. In the EU, the generic market will be affected until 2030.
  4. Patent term extensions (e.g., regulatory exclusivity adjustments) could shift these dates slightly, but the above dates represent the statutory expiration dates.

Bottom line

  • U.S.: The primary patent that covers dupilumab itself expires on March 3 2030; use‑patents extend exclusivity for specific indications up to 2038.
  • EU: The corresponding composition‑of‑matter patent and key use patents expire on March 3 2030.

These dates are based on the official U.S. Patent and Trademark Office (USPTO) and European Patent Office (EPO) records as of September 2026. If you need the most up‑to‑date information for a specific jurisdiction, please let me know!



Other Questions About Dupilumab :

Dupilumab patent expiry? Dupilumab patent? Dupilumab (dupixent) price? Dupilumab injection cost? Dupilumab patent expiry 2029? Dupilumab annual cost? Dupilumab biosimilar approved ema 2026?